Rocket Pharmaceuticals Inc
RCKT
Company Profile
Business description
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Contact
9 Cedarbrook Drive
CranburyNJ08512
USAT: +1 609 659-8001
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
202
Stocks News & Analysis
stocks
Margins have bottomed for ASX listed consumer goods company
Impact of tariffs have been priced in.
stocks
SpaceX rally continues, expanding sky-high valuations
SpaceX has risen 50% from its IPO price to become the second-most-expensive stock under Morningstar’s coverage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,039.10 | 17.30 | 0.19% |
| CAC 40 | 8,421.14 | 46.84 | -0.55% |
| DAX 40 | 24,985.82 | 40.98 | -0.16% |
| Dow JONES (US) | 51,564.70 | 72.15 | 0.14% |
| FTSE 100 | 10,363.27 | 36.43 | -0.35% |
| HKSE | 23,713.41 | 211.40 | -0.88% |
| NASDAQ | 26,517.93 | 496.28 | 1.91% |
| Nikkei 225 | 72,388.61 | 1,138.55 | 1.60% |
| NZX 50 Index | 13,446.05 | 49.58 | -0.37% |
| S&P 500 | 7,500.58 | 80.48 | 1.08% |
| S&P/ASX 200 | 8,824.40 | 22.50 | 0.26% |
| SSE Composite Index | 4,126.97 | 36.49 | 0.89% |